Pinnacle Life Science Private Limited

Pinnacle Life Science Private Limited, established on January 15, 2003, is a private limited company headquartered in Baddi, Himachal Pradesh, India. It operates under the Corporate Identification Number (CIN) U24232HP2003PTC030912. The company is a subsidiary of Aarti Drugs Limited, a prominent player in the pharmaceutical industry, and is part of the $1.5 billion Aarti Group conglomerate.

As of the latest available data, Pinnacle Life Science has an authorized share capital of ₹100 million and a paid-up capital of ₹77.8275 million. The company has experienced growth in recent years, with a 9.78% increase in total revenue for the financial year ending March 31, 2024. Profitability has also improved, with a 109.39% increase in profit during the same period.

Pinnacle Life Science operates a state-of-the-art manufacturing facility in Baddi, Himachal Pradesh. This plant has received approvals from the US FDA and multiple Good Manufacturing Practice (GMP) certifications, including those from the Medicines Control Authority of Zimbabwe (MCAZ) and the General Directorate of Medicines and Medical Devices of Peru (DIGEMID).

The company's leadership includes Managing Director Vishwa Harshit Savla, appointed on September 8, 2014, and Director Neha Rajen Gada, appointed on July 1, 2024. Other key executives include Harshit Manilal Savla, Harit Pragji Shah, Adhish Prakash Patil, and Parth Samir Shah.

Pinnacle Life Science has made significant strides in regulated markets. In April 2023, the company successfully completed a US FDA audit for its oncology block, marking a significant achievement in its global expansion efforts. Additionally, in June 2023, the company passed a UK Medicines and Healthcare products Regulatory Agency (MHRA) audit, further solidifying its presence in the European market.

The company has expanded its reach to over 90 countries, including emerging markets in Africa, Latin America, and Southeast Asia. Its manufacturing facility has received GMP approvals from regulatory bodies such as MCAZ Zimbabwe and DIGEMID Latin America, facilitating access to these regions.

Pinnacle Life Science's export portfolio is concentrated, with its top five products accounting for 100% of its export value. This indicates a high level of concentration risk. The company's strategic direction appears to focus on consolidating its position in key markets, leveraging its manufacturing capabilities and regulatory approvals to expand its global footprint.

Pinnacle Life Science's manufacturing facility in Baddi, Himachal Pradesh, has been registered with the US FDA. In April 2023, the company successfully completed a US FDA audit for its oncology block, marking a significant achievement in its global expansion efforts.

The company has received GMP approvals from the Medicines Control Authority of Zimbabwe (MCAZ) and the General Directorate of Medicines and Medical Devices of Peru (DIGEMID), facilitating access to these regions.

Pinnacle Life Science holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India. The company's registered address is Near Telephone Exchange, Manpura, Baddi, Himachal Pradesh 173205, India.

As of the latest available information, there are no records of Form 483 observations, warning letters, or import alerts issued to Pinnacle Life Science by regulatory authorities.

Pinnacle Life Science operates in a competitive landscape with several key players in the pharmaceutical export market. While specific market share data is not available, the company's focus on high-quality manufacturing and regulatory compliance positions it favorably against competitors.

Pinnacle Life Science's key differentiators include its state-of-the-art manufacturing facility in Baddi, Himachal Pradesh, which has received approvals from the US FDA and multiple GMP certifications. The company's diverse product portfolio spans oncology, cardiovascular, anti-infectives, and diabetes segments, catering to a wide range of therapeutic areas.

Pinnacle Life Science's current strategic direction focuses on expanding its presence in both regulated and emerging markets. The company's recent regulatory approvals and successful audits indicate a strong commitment to quality and compliance. Future outlook appears positive, with plans to launch new products in oncology, cardiovascular, and anti-infective segments.

Pinnacle Life Science has demonstrated a strong track record in manufacturing and exporting pharmaceutical products. The company's export value of $1.5 million USD across 40 shipments indicates a consistent export volume. The high concentration of its export portfolio suggests a focused approach, which may be advantageous for partners seeking specialized products.

Importers should verify the following certifications when considering Pinnacle Life Science as a supplier:

• FDA Registration: Confirm the company's registration status with the US FDA.

• WHO-GMP Certification: Verify the company's compliance with World Health Organization Good Manufacturing Practice standards.

• EU GMP Certification: Ensure the company holds European Union Good Manufacturing Practice certification.

• ISO Certification: Check for relevant ISO certifications related to quality management systems.

When conducting due diligence on Pinnacle Life Science, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's certifications and approvals from relevant regulatory bodies.

• Assess Financial Health: Review the company's financial statements for profitability and growth trends.

• Evaluate Manufacturing Capabilities: Inspect the manufacturing facility for compliance with international standards.

• Review Product Portfolio: Analyze the company's product offerings to ensure alignment with market needs.

• Check References: Seek feedback from existing clients and partners regarding the company's reliability and product quality.

Be cautious of any discrepancies in regulatory certifications or financial statements, as these may indicate potential risks.